## Maralixibat chloride

Cat. No.:	HY-16747	
CAS No.:	228113-66-4	
Molecular Formula:	C <sub>40</sub> H <sub>56</sub> ClN <sub>3</sub> O <sub>4</sub> S	
Molecular Weight:	710.41	
Target:	Apical Sodium-Dependent Bile Acid Transporter	
Pathway:	Membrane Transporter/Ion Channel	O <sup>S</sup>
Storage:	4°C, sealed storage, away from moisture	
	* In solvent : -80°C, 6 months: -20°C, 1 month (sealed storage, away from moisture)	

## SOLVENT & SOLUBILITY

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.4076 mL	7.0382 mL	14.0764 mL
	5 mM	0.2815 mL	1.4076 mL	2.8153 mL
	10 mM	0.1408 mL	0.7038 mL	1.4076 mL

BIOLOGICAL ACTIVITY		
Description	Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia <sup>[1][2]</sup> .	
In Vivo	Maralixibat chloride reduces elevations in sBA levels, improves liver function, and reduces liver tissue damage, in a rat partial bile duct ligation model of cholestasis <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## REFERENCES

Page 1 of 2

[1]. Mayo MJ, et al. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatol Commun. 2019 Feb 1;3(3):365-381.

[2]. Shirley M. Maralixibat: First Approval [published correction appears in Drugs. 2021 Dec 6;;]. Drugs. 2022;82(1):71-76.





## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA